Research Article - (2010) Volume 1, Issue 1

Phase 2 Trial of V-5 Immunitor (V5) in Patients with Chronic Hepatitis C Co-infected with HIV and Mycobacterium Tuberculosis

Olga V. Arjanova1, Nathalia D. Prihoda1, Larisa V. Yurchenko1, Nina I. Sokolenko1, Valery M. Frolov2, Marina G Tarakanovskaya3, Vichai Jirathitikal4 and Aldar S. Bourinbaiar5*
1Lisichansk Regional Tuberculosis Dispensary, Lisichansk, Ukraine, E-mail: OlgaVArjanova@gmail.com
2Luhansk State Medical University, Luhansk, Ukraine, E-mail: OlgaVArjanova@gmail.com
3Ekomed LLC, Ulaanbaatar, Mongolia, E-mail: OlgaVArjanova@gmail.com
4Immunitor Thailand Co., LLC, Thailand, E-mail: OlgaVArjanova@gmail.com
5Immunitor USA Inc., College Park, MD 20740, USA, E-mail: OlgaVArjanova@gmail.com
*Corresponding Author: